AKEBIA THERAPEUTICS, INC.

(AKBA)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
0.4134 USD   +3.71%
08/11PUBLIC DISCLOSURE VS. CONFIDENTIALITY PROTECTION : The FCA Finds The Proper Balance
AQ
08/05Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome
AQ
08/04AKEBIA THERAPEUTICS : Q2 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Akebia Therapeutics to Present at Jefferies London Healthcare Conference

11/15/2021 | 08:31am EDT

CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, which takes place November 16 – 19, 2021.

The on-demand presentation will be available beginning at 8:00 a.m. GMT on November 18 through the conference site. The webcast will also be available through the Investors section of the Company's website at https://ir.akebia.com for approximately 30 days following the conference.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
Mcarrasco@akebia.com 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-jefferies-london-healthcare-conference-301423656.html

SOURCE Akebia Therapeutics


© PRNewswire 2021
All news about AKEBIA THERAPEUTICS, INC.
08/11PUBLIC DISCLOSURE VS. CONFIDENTIALIT : The FCA Finds The Proper Balance
AQ
08/05Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Stu..
AQ
08/04AKEBIA THERAPEUTICS : Q2 Earnings Snapshot
AQ
08/04AKEBIA THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Recent Business Hi..
PU
08/04AKEBIA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/04TRANSCRIPT : Akebia Therapeutics, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04Akebia Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/04AKEBIA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD D..
AQ
08/04Akebia Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2022
CI
08/04Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q2 Revenue $126.8M
MT
More news
Analyst Recommendations on AKEBIA THERAPEUTICS, INC.
More recommendations